Research article

Effects of intravenous furosemide on mucociliary transport and rheological properties of patients under mechanical ventilation

Cláudia Seiko Kondo*†, Mariângela Macchionne*, Naomi Kondo Nakagawa*†, Carlos Roberto Ribeiro de Carvalho*, Malcolm King‡, Paulo Hilário Nascimento Saldiva*, Geraldo Lorenzi-Filho*

*Universidade de São Paulo, São Paulo, Brazil
†Universidade Federal de São Paulo and Escola Paulista de Medicina, São Paulo, Brazil
‡Pulmonary Research Group, Edmonton, Alberta, Canada

Introduction

Although mechanical ventilation (MV) is necessary to improve ventilatory support in respiratory failure, it is generally known that this procedure markedly increases the incidence of pulmonary infection and consequently the morbidity and mortality of patients. Mucociliary clearance has been reported to be impaired in patients under MV and this is probably an important underlying mechanism in the pathogenesis of pulmonary infection in these patients [1]. Mucociliary clearance has a pivotal role in the protection of the respiratory tract against inhaled noxious agents that are trapped in the blanket of mucus and transported towards the pharynx by ciliary beating or coughing. The efficiency of the mucociliary system depends not only on the integrity of the epithelium and on ciliary activity but also on the amount of mucus, the depth of the periciliary layer and the viscoelastic properties of mucus [2].

Abstract

The use of intravenous (IV) furosemide is common practice in patients under mechanical ventilation (MV), but its effects on respiratory mucus are largely unknown. Furosemide can affect respiratory mucus either directly through inhibition of the NaK(Cl)₂ co-transporter on the basolateral surface of airway epithelium or indirectly through increased diuresis and dehydration. We investigated the physical properties and transportability of respiratory mucus obtained from 26 patients under MV distributed in two groups, furosemide (n=12) and control (n=14). Mucus collection was done at 0, 1, 2, 3 and 4 hours. The rheological properties of mucus were studied with a microrheometer, and in vitro mucociliary transport (MCT) (frog palate), contact angle (CA) and cough clearance (CC) (simulated cough machine) were measured. After the administration of furosemide, MCT decreased by 17 ± 19%, 24 ± 11%, 18 ± 16% and 18 ± 13% at 1, 2, 3 and 4 hours respectively, \( P<0.001 \) compared with control. In contrast, no significant changes were observed in the control group. The remaining parameters did not change significantly in either group. Our results support the hypothesis that IV furosemide might acutely impair MCT in patients under MV.

Keywords: furosemide, mechanical ventilation, mucociliary transport, mucus rheology

Received: 14 February 2001
Revisions requested: 31 August 2001
Revisions received: 19 September 2001
Accepted: 23 October 2001
Published: 19 November 2001

Critical Care 2002, 6:81-87

© 2002 Kondo et al., licensee BioMed Central Ltd (Print ISSN 1364-8535; Online ISSN 1466-609X)
secretion or absorption of water. Pulmonary epithelial ion transport systems are important in the modulation of the ionic content and volume of periciliary fluid, which in turn modulates the physical properties and transportability of mucus. Small changes in the depth of periciliary fluid could greatly alter the efficiency of interaction between mucus and cilia [4]. Diuretics with an action on ionic channels present in the airway epithelium can alter ionic movement and change the physical properties and transportability of mucus. For instance, inhaling amiloride, a diuretic with action on the apical Na⁺ channel, has been reported to increase mucociliary clearance and alter the physical properties of mucus in patients with cystic fibrosis [5–8].

Intravenous (IV) furosemide is frequently used in patients under MV with the aim of equilibrating a cumulative positive fluid balance. However, the possible effects of IV furosemide on respiratory mucus are largely ignored. Furosemide is a potent diuretic that acts by inhibiting the NaK(Cl)₂ co-transporter in the ascending limb of the loop of Henle. Besides its renal action, furosemide can also affect epithelial ion transport in the airway. Earlier studies demonstrated that furosemide inhibits the NaK(Cl)₂ co-transporter in canine airway epithelium [9] and also decreases intracellular Cl⁻ activity in cultured human airway epithelium [10]. The effects of inhaled furosemide have also been investigated. Inhaled furosemide prevents exercise-induced bronchoconstriction in asthmatic patients [11]. Hasani et al. [12] reported that inhaled furosemide had no effects on mucociliary clearance in humans. However, the primary site of furosemide action is the basolateral membrane of the airway, where it inhibits the NaK(Cl)₂ co-transporter. Therefore the effects of the drug on the respiratory epithelium might depend on the route of administration. The aim of the present study was to investigate the effects of IV furosemide on the transportability and rheological properties of mucus in patients under MV.

**Materials and methods**

**Patients**

We studied 26 patients under MV in the Respiratory Intensive Care Unit of the Pulmonary Division, Hospital das Clínicas, University of São Paulo. The study was approved by the Ethics Committee of the University of São Paulo. All patients were clinically and haemodynamically stable for at least 24 hours before the study. In each of these patients we registered their clinical data, including arterial pressure, heart rate, fluid balance, urine output and temperature, during the 24 hours before and during the study. We also registered the mode of MV, tidal volume, respiratory rate, minute volume, fraction of inspired oxygen and system of humidification. The time interval between the initiation of MV and the study was also recorded.

The patients were distributed in two groups: the furosemide group consisted of 12 patients (8 female and 4 male) who received IV furosemide; the control group consisted of 14 patients (3 female and 11 male) who did not receive any diuretic during the study. Their ages (means ± SD) in the furosemide and control groups were, respectively, 66 ± 15 years with a range of 30–82 years, and 49 ± 20 years with a range of 20–76 years. The indication and dose of furosemide were determined by each patient’s clinical conditions and in all cases were because of a positive fluid balance. The aim of including a control group was to make sure that there were no time-dependent changes in the variables analysed. When recruiting patients for the control group, our main goal was to match them in terms of the MV parameters.

**Collection of mucus**

Respiratory mucus was collected from the endotracheal tube by sterile technique with a suction catheter. The samples were extracted from the catheter with a sterile needle and were immediately immersed in mineral oil to prevent mucus dehydration. The suction conditions were kept to a minimum to decrease the degree of shear thinning and the incorporation of air bubbles [13]. Mucus samples were stored at −70°C in sealed plastic containers for later analysis.

We collected mucus at 0, 1, 2, 3 and 4 hours. The first sample (0 hours) in the furosemide group was just before the administration of the diuretic.

**Mucus analysis**

*Mucus transportability by cilia*

Mucociliary transport (MCT) was determined in vitro in the frog palate preparation, which possesses an epithelium that is similar to that in the upper airways in humans [14]. All animals were cared for in compliance with the Guide for Care and Use of Laboratory Animals published by the National Institutes of Health (NIH publication 85-23, revised 1985). To deplete the palate mucus, the palate was stored for 2 days at 4°C in a humidified chamber covered with plastic wrap [15]. Ciliary activity is maintained under these experimental conditions. The frog mucus was collected and used as a control for measurements of transport rate. Measurements of transport rate were determined with a stereomicroscope (Zeiss) equipped with a reticulated eyepiece. We timed the displacement of the mucus samples across a segment between the anterior and posterior parts of the palate. During the experiments the palate was kept at ambient temperature (20–25°C) and 100% humidity, provided by ultrasonic nebulization [13,16]. The results were expressed as relative transport velocity and corresponded to the ratio of velocity of the test mucus sample to that of the control frog mucus.

*Contact angle (CA)*

Respiratory mucus is a complex material that possesses both rheological properties, which are directly involved in the transportability of mucus, and physical properties such as wettability, which is an important property in the interaction between the mucus and the respiratory epithelial surface. Wettability is the tendency of a biological fluid to spread when deposited.
on a solid plane surface owing to the interaction between the surface and the molecules of the mucus. The degree of wettability is determined by the contact angle between the tangent to the liquid–air interface and the horizontal at the triple point where the three phases meet [17].

CA was determined by an eyepiece that had a goniometer with a scale of 0° to 180°. Mucus samples were placed on a plate pretreated with sulphochromic acid to remove electrical charges, which interfered with measurements. During the experiments a water bath kept at 37°C allowed humidification to prevent the dehydration of mucus [13,16].

**Mucus transportability by cough**

Cough clearance (CC) experiments were performed in vitro in a simulated cough machine adapted from King et al. [18]. This machine consisted of a cylinder of compressed air serving as gas supply, a solenoid valve that controlled the release of gas, and a cylindrical acrylic tube 4 mm in internal diameter and 133 mm in length as a model trachea. Mucus was introduced into the tube and connected to the simulated cough machine. The solenoid valve released the air for 0.5 s under a pressure of 280 kPa. Clearance was quantified by determining the displacement of mucus in millimetres [13,16].

**Rheological properties**

The rheological properties of mucus samples were determined in the present study with a magnetic microrheometer as described by King and Macklem [19] and modified by Silva et al. [20]. The microrheometer measured the displacement, resulting from a sinusoidal oscillating magnetic field, of a small steel ball inserted in the mucus sample. The motion of the ball was opposed by viscous and elastic forces.

The plexiglass container with the drop of mucus sample and the steel ball was placed into the gap of a magnetic toroid that was mounted on the stage of a projecting microscope and driven by a sine-wave generator. The shadow of the ball was projected onto two photocells that captured its oscillatory movement, resulting from a sinusoidal oscillating magnetic field, of a small steel ball inserted in the mucus sample. The motion of the ball was opposed by viscous and elastic forces. The results of the remaining parameters, contact angle, log G* and tan δ measured at 1 and 100 radians/s, are presented in Table 3. There were no significant differences between groups.

**Statistical analysis**

Statistical analysis was performed by profile analysis [13], which takes into account time correlation between different sampling times (0, 1, 2, 3 and 4 hours). This is a multivariate method in which only one statistical model is applied. This method considers the group along the time and basic hypotheses can be tested enabling post hoc corrections to be performed through contrasts so as to identify, or discriminate, significant differences. Basic hypotheses are the following: H₀₁, in which there is no interaction between the factors group and time (parallelism); H₀₂ in which there is no difference between the use of either control or furosemide group (coincidence); and H₀₃, in which there is no time effect.

When H₀₁ was accepted, hypotheses H₀₂ and H₀₃ were tested. When H₀₁ was rejected, hypotheses H₀₂ and H₀₃ were not tested and post hoc corrections for multiple comparisons were performed through contrasts.

\( P < 0.05 \) was considered statistically significant.

**Results**

Demographic and MV parameters are described in Tables 1 and 2. The time lag between the initiation of MV and the study was 9 ± 6 and 9 ± 6 days for the furosemide and control groups, respectively (\( P = 0.9 \)). In the furosemide group, two patients were using the heat and moisture exchanger (HME), and 10 were using the heated humidifier. In the control group, six patients were using the HME and eight were using the heated humidifier.

The results of mucus transportability in the frog palate (MCT) and cough (CC) are presented in Figs 1 and 2, respectively. MCT decreased significantly after furosemide administration and did not recover to baseline values by 4 hours (\( P=0.0001 \)). In contrast, MCT remained constant in the control group (Fig. 1). There was a trend that did not reach statistical significance for a decrease in CC in the furosemide group (Fig. 2).

The results of the remaining parameters, contact angle, log G* and tan δ measured at 1 and 100 radians/s, are presented in Table 3. There were no significant differences between groups.

**Discussion**

To our knowledge this is the first study to investigate the effects of IV furosemide on mucus transportability in vitro and the physical properties of mucus from patients under MV. Our results suggest that IV furosemide might acutely impair MCT for up to 4 hours after administration.

The mucociliary escalator of the lungs is an important protective transport system by means of which inhaled particles and microorganisms are removed from the tracheobronchial system. Lung mucociliary clearance is influenced by several factors, including the integrity of the ciliated epithelium and the thickness and physical properties of the periciliary or mucous layer [12]. Under normal circumstances, active ion transport in the respiratory epithelium is important in the pro-
duction and regulation of the volume and composition of the respiratory tract secretion, which in turn is important for adequate mucociliary interaction [22]. Pharmacological interference in ionic transport is caused by a new class of drugs that can change MCT. For instance, inhalation of amiloride increases MCT in patients with cystic fibrosis by inhibiting the active absorption of salt and water from airway surfaces [23,24].

The effects of furosemide on the respiratory epithelium have attracted interest in the decade since Bianco et al. [11] reported that inhaled furosemide prevents exercise-induced bronchoconstriction in asthmatic patients. The mechanism of this protective effect remains to be established. The effects of inhaled furosemide on mucociliary clearance have been investigated and the results are controversial. Hasani et al. [12] reported that nebulized furosemide does not affect mucociliary clearance measured with a radioaerosol technique in healthy and asthmatic subjects. It must be stressed that the primary site of furosemide action is the basolateral membrane of the airway, where it inhibits the NaK(Cl)2 co-transporter. Inhaled furosemide might therefore not reach the basolateral membrane of airway epithelial cells in vivo [11,25]. In fact, experimental studies have demonstrated that, in contrast with the serosal application of furosemide, mucosal application has no effect on co-transporter function [26]. Winters and Yeates [27] have reported an increase in lung mucociliary clearance in vivo after the inhalation of aerosolized furosemide and the IV administration of furosemide in dogs and baboons. However, in this study the

| Sex | Age | Diagnosis                                | Mode    | $F_{O_2}$ (%) | $V_{E}$ (L/min) | Vasoactive drugs | Tracheal secretion | Fluid balance (ml) | Diuresis (ml) |
|-----|-----|------------------------------------------|---------|---------------|----------------|------------------|-------------------|------------------|--------------|
| F   | 70  | Mediastinal tumor resection              | AMV     | 40            | 11.7           | –                | S. viridans       | +31              | +233         |
| M   | 20  | Head trauma                              | VAPS    | 45            | 9.6            | –                | P. aeruginosa     | +78              | –10          |
| M   | 20  | Head trauma                              | VAPS    | 40            | 9.2            | –                | P. aeruginosa     | +341             | +83          |
| M   | 63  | Cerebrovascular accident, heart failure, osteomyelitis | VAPS    | 46            | 10.5           | Dobutamine       | A. calcoaceticus  | +1310            | –154         |
| M   | 47  | Lung neoplasm                            | SIMV    | 40            | 9.7            | Dobutamine       | –                | +564             | +321         |
| M   | 76  | Lung neoplasm, pneumonia                  | AMV     | 36            | 8.7            | Dobutamine       | P. aeruginosa     | +1408            | +132         |
| M   | 66  | Heart failure, pneumonia, pulmonary lobectomy | PC     | 50            | 8.7            | Dobutamine       | A. calcoaceticus  | +534             | +373         |
| M   | 22  | Craniotomy, pneumonia                     | AMV     | 40            | 9.4            | –                | A. calcoaceticus  | +1411            | +171         |
| M   | 41  | Hyperosmolar coma, cerebrovascular accident | PC/SIMV | 40            | 10.7           | –                | A. baumanii      | –518             | +86          |
| M   | 61  | Lung neoplasm, COPD, acute renal insufficiency | PS     | 45            | 11.7           | Dobutamine       | S. marcescens    | +1871            | +183         |
| F   | 58  | Drug intoxication, pneumonia              | PC/SIMV | 40            | 7.7            | –                | S. aureus        | +286             | –98          |
| M   | 74  | Pulmonary tumor resection                 | AMV     | 30            | 8.3            | –                | –                | –462             | +133         |
| M   | 51  | Respiratory failure                       | PC/SIMV | 40            | 10.5           | Noradrenaline    | –                | +1452            | –59          |
| F   | 23  | Thyroidectomy                             | SIMV    | 40            | 5.0            | –                | –                | +3551            | +290         |
| Mean | 50  |                                        |         | 40            | 9.4            | –                | –                | 671              | 82           |

Abbreviations: AMV, assisted mechanical ventilation; COPD, chronic obstructive pulmonary disease; $F_{O_2}$, fraction of inspired oxygen; PC, pressure-controlled ventilation; PS, pressure-support ventilation; SIMV, synchronized intermittent mandatory ventilation; VAPS, volume-assured pressure support, $V_{E}$, minute volume. *P < 0.05.
properties and in vitro transportability of mucus were not determined.

In our study we observed a decrease in MCT after furosemide administration that did not recover to the baseline by 4 hours. Furosemide inhibits the NaK(Cl)_2 co-transporter, which is one of the physiological mechanisms involved in the respiratory hydration of mucus; its inhibition could therefore interfere in the rheological properties of mucus [4,28]. The ionic concentration of Na^+ and Cl^− in mucus can also influence the rheology and transportability of mucus independently of its total water content [6,29]. In addition, diuresis might lead to systemic dehydration and impairment of mucociliary clearance [30,31]. In our study, furosemide administration was a clinical decision based on cumulative positive fluid balance and determined by the medical staff. Interestingly, the furosemide and control groups had similar fluid balance in the 24 hours before the onset of the study. As expected, furosemide promoted increased diuresis. It must be stressed that in our study the patients were not monitored invasively. Fluid balance, diureses and haemodynamic status can give only gross estimates of fluid balance. In summary, from this study it is not possible to determine the mechanism involved in the effects of furosemide on MCT.

The mode of humidification was not uniform between the groups. Nakagawa et al. [13] have recently compared the effects of two systems of humidification (HME with a Pall BB 100 F, and a heated humidifier) on respiratory mucus and its transportability in patients under MV. The effects were evaluated for up to 72 hours of MV. They observed a decrease in CC in the HME group only after 72 hours of MV. Because the present study was limited to an intervention in a short period (4 hours), baseline clinical conditions, including age, MV parameters and the mode of humidification, probably did not influence the results. Indeed, our control group showed no time-dependent changes in all parameters studied. Infection also affects respiratory mucus and epithelium. However, the occurrence of pulmonary infection was similar in both groups (10 patients in the control group and 9 in the furosemide group), suggesting that this factor did not influence our results.

### Table 2

| Sex | Age | Diagnosis                  | Mode       | F_{O2} (%) | V_{E} (L/min) | Vasoactive drugs | Tracheal secretion | Fluid balance (ml) | Diuresis (ml) |
|-----|-----|----------------------------|------------|------------|---------------|------------------|-------------------|-------------------|---------------|
| F   | 61  | Pneumonia                  | VAPS       | 45         | 7.5           | –                | X. malophilia     | +380              | −15           | 2600         | 500          |
| F   | 64  | Acute renal failure        | CMV        | 45         | 6.9           | Noradrenaline    | S. aureus         | +768              | +178          | 482          | 275          |
| M   | 66  | Pulmonary lobectomy, failure | SIMV       | 40         | 8.6           | Dobutamine       | P. aeruginosa A. calcoaceticus | +1175             | −200          | 1580         | 540          |
| M   | 30  | Wound of gunshot injury    | SIMV       | 30         | 4.7           | –                | –                 | +960              | −1475         | 1250         | 1800         |
| F   | 86  | Burn                       | PC         | 40         | 4.2           | Dobutamine       | –                 | −610              | −366          | 3400         | 860          |
| F   | 69  | Penetrating thorax wound   | CPAP       | 40         | 5.8           | –                | –                 | −740              | −734          | 1750         | 890          |
| F   | 82  | Pneumonia                  | AMV        | 50         | 8.6           | –                | A. calcoaceticus  | +1242             | +264          | 1440         | 300          |
| F   | 82  | Pneumonia                  | AC         | 45         | 9.5           | –                | A. calcoaceticus  | +418              | +192          | 1120         | 540          |
| F   | 67  | Sjogren syndrome           | CMV        | 40         | 8.7           | –                | P. aeruginosa     | +502              | +604          | 1850         | 200          |
| M   | 74  | Wegener’s granulomatosis, pneumonia | VAPS     | 40         | 12            | Dopamine         | P. malophilia     | +1988             | −1194         | 1670         | 1700         |
| M   | 61  | COPD, respiratory failure  | PC         | 60         | 9.9           | Dopamine         | S. marcescens A. baumanii X. malophilia | +2244             | −1           | 290          | 100          |
| F   | 63  | Cerebrovascular accident, PE, pneumonia | AC   | 55         | 8.9           | Dobutamine       | A. calcoaceticus  | +2190             | −22           | 1460         | 440          |
| Mean| 66.2| ±14.7|                        | 44         | 8.3           | ±8 ±2.1          | ±1036 ±616 ±836 ±554 | ±1036 ±616 ±836 ±554 | ±1036 ±616 ±836 ±554 |

Abbreviations: AC, assist/control ventilation; AMV, assisted mechanical ventilation; CMV, controlled mechanical ventilation; COPD, chronic obstructive pulmonary disease; F_{O2}, fraction of inspired oxygen; PC, pressure-controlled ventilation; PE, pulmonary embolism; SIMV, synchronized intermittent mandatory ventilation; CPAP, continuous positive airway pressure; VAPS, volume-assured pressure support, V_{E}, minute volume.

*P < 0.05.
In our study, impairment in MCT was not matched with significant changes in other physical properties of mucus. It is possible that MCT is a more sensitive method for detecting mucociliary impairment. Because our study involved a relatively small number of patients, we cannot discard a type 2 error to explain the absence of furosemide effect on other mucus parameters. An alternative explanation is that furosemide has direct effects on the ciliary beating frequency of the frog palate.

Table 3

| Time (hours) | MCT (relative speed) | CA (degrees) | CC (mm) | logG*, 1 radian/s |
|--------------|----------------------|--------------|---------|-----------------|
|              | C        | F           | C        | F           | C        | F          | C        | F          |
| 0            | 0.83 ± 0.22 | 1.01* ± 0.21 | 44.14 ± 8.78 | 37.75 ± 8.13 | 58.21 ± 30 | 74.25 ± 29.46 | 1.66 ± 0.38 | 1.45 ± 0.43 |
| 1            | 0.88 ± 0.24 | 0.81 ± 0.16 | 45.43 ± 8.53 | 41.25 ± 10.9 | 60.43 ± 29 | 62.5 ± 29.44 | 1.49 ± 0.44 | 1.57 ± 0.49 |
| 2            | 0.85 ± 0.21 | 0.77 ± 0.2 | 44.93 ± 8.11 | 40.92 ± 7.8 | 63.6 ± 37.44 | 46.92 ± 28.6 | 1.62 ± 0.35 | 1.55 ± 0.42 |
| 3            | 0.88 ± 0.2 | 0.82 ± 0.22 | 45 ± 10.2 | 41.75 ± 9 | 57.6 ± 34.25 | 63.1 ± 28.93 | 1.37 ± 0.57 | 1.61 ± 0.38 |
| 4            | 0.88 ± 0.18 | 0.82 ± 0.2 | 44.29 ± 6.29 | 39.92 ± 11.4 | 60.57 ± 26.57 | 57.75 ± 31.22 | 1.46 ± 0.4 | 1.48 ± 0.27 |
| P            | 0.88      | 0.0001*     | 0.25      |              | 0.54      |              | 0.60      |              |

| Time (hours) | logG*, 100 radians/s | tanδ, 1 radian/s | tanδ, 100 radians/s |
|--------------|----------------------|-----------------|-------------------|
|              | C        | F           | C        | F           | C        | F          |
| 0            | 1.65 ± 0.24 | 1.61 ± 0.42 | 0.51 ± 0.12 | 0.51 ± 0.19 | 0.73 ± 0.22 | 0.84 ± 0.41 |
| 1            | 1.68 ± 0.3 | 1.71 ± 0.38 | 0.57 ± 0.14 | 0.54 ± 0.25 | 0.75 ± 0.23 | 0.79 ± 0.34 |
| 2            | 1.67 ± 0.35 | 1.69 ± 0.26 | 0.49 ± 0.13 | 0.61 ± 0.26 | 0.86 ± 0.27 | 0.78 ± 0.26 |
| 3            | 1.40 ± 0.36 | 1.71 ± 0.32 | 0.47 ± 0.15 | 0.63 ± 0.36 | 0.63 ± 0.17 | 0.72 ± 0.16 |
| 4            | 1.51 ± 0.23 | 1.62 ± 0.25 | 0.6 ± 0.15 | 0.57 ± 0.14 | 0.66 ± 0.22 | 0.82 ± 0.39 |
| P            | 0.16      | 0.16        | 0.14      |              |              |              |

Abbreviations: C, control group; CA, contact angle; CC, cough clearance; F, furosemide group; MCT, mucociliary transport. *P < 0.05.

In our study, impairment in MCT was not matched with significant changes in other physical properties of mucus. It is possible that MCT is a more sensitive method for detecting mucociliary impairment. Because our study involved a relatively small number of patients, we cannot discard a type 2 error to explain the absence of furosemide effect on other mucus parameters. An alternative explanation is that furosemide has direct effects on the ciliary beating frequency of the frog palate.
In conclusion, our preliminary results support the hypothesis that IV furosemide might acutely impair mucociliary clearance. In patients with respiratory failure and MV, many factors can potentially impair MCT, such as ventilation with a high concentration of oxygen, the activation of inflammatory mediator systems, colonization by bacteria, suction-induced lesions of the mucous membrane, infections and drugs [1]. The mechanisms and the clinical relevance of our findings remain to be established.

**Competing interests**

None declared.

**References**

1. Konrad F, Schiener R, Marx T, Georgiev M: Ultrastructure and mucociliary transport of bronchial respiratory epithelium in intubated patients. *Intensive Care Med* 1995, 21:482-489.
2. Sleigh MA, Blake JR, Liron N: The propulsion of mucus by cilia. *Am Rev Respir Dis* 1988, 137:726-741.
3. Frizzel RA: Role of absorptive and secretory processes in hydration of the airway surface. *Am Rev Respir Dis* 1988, 138: S3-S6.
4. Trout L, King M, Feng W, Inglis SK, Ballard ST: Inhibition of airway liquid secretion and its effect on the physical properties of airway mucus. *Am J Physiol* 1997, 272:L372-L377.
5. Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gillick P, King M, Edwards LJ, Heils RW, Boucher RC: A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. *N Engl J Med* 1990, 322:1189-1194.
6. Tomkiewicz RP, App EM, Zayas JG, Ramirez O, Church N, Boucher RC, Knowles MR, King M: Amiloride inhalation therapy in cystic fibrosis: influence on ion content, hydration, and rheology of sputum. *Am Rev Respir Dis* 1993, 148:1002-1007.
7. Boucher RC: Human airway transport – part two. *Am J Respir Crit Care Med* 1994, 150:581-593.
8. Knowles MR, Olivier KN, Hohnekker KW, Robinson J, Bennett WD, Boucher RC: Pharmacologic treatment of abnormal ion transport in the airway epithelium in cystic fibrosis. *Chest* 1995, 107 (suppl):71S-76S.
9. Widdicombe JH, Nathanson IT, Highland E: Effects of ‘loop’ diuretics on ion transport by dog tracheal epithelium. *Am J Physiol* 1983, 245:C389-C396.
10. Willumsen NJ, Davis OW, Boucher RC: Intracellular Cl– activity and cellular Cl– pathways in cultured human airway epithelium. *Am J Physiol* 1989, 256:C1003-C1044.
11. Bianco S, Robuschi M, Vaghi A, Persagianli M: Prevention of exercise-induced bronchoconstriction by inhaled frusemide. *Lancet* 1988, 2:252-255.
12. Hasani A, Pavia D, Spiteri MA, Yeo CT, Agnew JE, Clarke SW, Chung KF: Inhaled frusemide does not affect lung mucociliary clearance in healthy and asthmatic subjects. *Eur Respir J* 1994, 7:1497-1500.
13. Nakagawa NK, Macchione M, Petrolino HMS, Guimarães ET, King M, Saldiva PHN, Lorenzi-Filho G: Effects of a heat and moisture exchanger and a heated humidifier on respiratory mucus in patients undergoing mechanical ventilation. *Crit Care Med* 2000, 28:312-317.
14. Şade J, Elezeer N, Silberberg A, Nevo AC: The role of mucus in transport by cilia. *Am Rev Respir Dis* 1970, 102:48-52.
15. Rubin BK, Ramirez O, King M: Mucus-depleted frog palate as a model for the study of mucociliary clearance. *J Appl Physiol* 1990, 68:424-429.
16. Macchiione M, Guimarães ET, Saldiva PHN, Lorenzi-Filho G: Methods for studying respiratory mucus and mucus clearance. *Braz J Med Biol Res* 1995, 28:1347-1355.
17. Girou S, Zahn JM, Plotkowski C, Beck G, Puchelle E: Role of the physicochemical properties of mucus in the protection of the respiratory epithelium. *Eur Respir J* 1992, 5:477-487.
18. King M, Brock G, Lundell C: Clearance of mucus by simulated cough. *J Appl Physiol* 1985, 58:1776-1782.
19. King M, Macklem PT: The rheological properties of microlite quantities of normal mucus. *J Appl Physiol* 1977, 42:797-802.
20. Silva, PSP, Bohm GM, Yang HM, Wen CL, Guimarães ET, Parada MAC, King M, Saldiva PHN: Computer-assisted rheological evaluation of microsamples of mucus. *Comput Methods Programs Biomed* 1992, 39:51-60.
21. Lorenzi G, Böhm GM, Guimarães ET, Costa Váz MA, King G, Saldiva PHN: Correlation between rheologic properties and in vitro ciliary transport of rat nasal mucus. *Bioheology 1992, 29: 433-440.
22. King M: Experimental models for studying mucociliary clearance. *Eur Respir J* 1998, 11:222-228.
23. Knowles MR, Stutts J, Yankaskas JR, Gatzky JT, Boucher RC: Abnormal respiratory epithelial ion transport in cystic fibrosis. *Clinics Chest Med* 1986, 7:285-297.
24. App EM, King M, Hellesnieder R, Köhler D, Matthys H: Acute and long-term amiloride inhalation in cystic fibrosis lung disease: a rational approach to cystic fibrosis therapy. *Am Rev Respir Dis* 1990, 141:605-612.
25. Nichol GM, Alton EWF, Nix A, Gaddes DM, Chung KF, Barnes PJ: Effects of inhaled furosemide on metabisulfite and methacholine-induced bronchoconstriction and nasal potential difference in asthmatic subjects. *Am Rev Respir Dis* 1990, 142: 576-580.
26. Welch MJ: Inhibition of chloride secretion by furosemide in canine tracheal epithelium. *J Membr Biol* 1983, 71:219-226.
27. Winters SL, Yeates DB: Interaction between ion transporters and the mucociliary transport system in dog and baboon. *J Appl Physiol* 1997, 83:1348-1359.
28. Boucher RC: Human airway transport – part one. *Am J Physiol* 1994, 267:R785-R792.
29. Wills PJ, Roderick LH, Chan W, Cole PJ: Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. *J Clin Invest* 1997, 99:9-13.
30. Chopra SK, Taplin GV, Simmons DH, Robinson GD, Elam D, Coulson A: Effects of hydration and physical therapy on tracheal velocity. *Am Rev Respir Dis* 1977, 115:1009-1014.
31. Marchette LC, Marchette BE, Abraham WM, Wanner A: The effect of systemic hydration on normal and impaired mucociliary function. *Ped Pulmonol* 1985, 1:107-111.